Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 5/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19048139 | 0.86 | KDM1A (0.61) | KDM1AHTR7SIGMAR1ALDH1A1GBA1 | |
| SCHEMBL6568486 | 0.83 | SIGMAR1 (0.72) | KDM1AHTR7SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL4196782 | 0.82 | SIGMAR1 (0.73) | KDM1AHTR7SIGMAR1KDM4ELMNA | |
| SCHEMBL17374138 | 0.81 | HTR7 (0.66) | KDM1AHTR7SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL29172771 | 0.79 | HTR7 (0.60) | KDM1AHTR7SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL3719058 | 0.79 | PKM (0.69) | HTR7ALDH1A1PKM | |
| SCHEMBL3889428 | 0.79 | HTR7 (0.68) | KDM1AHTR7SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL25758479 | 0.78 | KDM1A (0.58) | KDM1AHTR7SIGMAR1KDM4ELMNA | |
| SCHEMBL24069354 | 0.77 | PRMT6 (0.56) | KDM4ESMN1; SMN2 | |
| SCHEMBL26213056 | 0.77 | KDM1A (0.53) | KDM1AHTR7SIGMAR1ALDH1A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101395150-A | Phenethanolamine derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | CN | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | KDM1A 2874/4885HTR7 136/4885SIGMAR1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.